Tofacitinib citrate 540737-29-9 Rheumatoid ogbu na nkwonkwo Anticancer
Ụgwọ:T/T, L/C
Isi mmalite ngwaahịa:China
Ọdụ ụgbọ mmiri:Beijing/Shanghai/Hangzhou
Ike mmepụta:100kg / ọnwa
Nye iwu (MOQ):25kg
Etiti oge:3 ụbọchị ọrụ
Ọnọdụ nchekwa:Echekwara ya na ebe dị jụụ, ebe akọrọ, okpomọkụ ụlọ.
Ihe ngwugwu:drum
Nha ngwugwu:25kg/drum
Ozi nchekwa:Ọ bụghị ngwongwo dị ize ndụ
Okwu mmalite
Tofacitinib, bụ ọgwụ a na-eji agwọ ọrịa ogbu na nkwonkwo, ọrịa ogbu na nkwonkwo, na ulcerative colitis.
A na-eji Tofacitinib citrate na-agwọ ndị okenye nwere ọrịa ogbu na nkwonkwo na-arụ ọrụ nke ọma na nke na-arụsi ọrụ ike bụ ndị nwere nzaghachi na-ezughị ezu na, ma ọ bụ ndị na-anabataghị, methotrexate.
A na-egosi Tofacitinib citrate maka ọgwụgwọ ọrịa ogbu na nkwonkwo na-arụ ọrụ nke ọma na nke siri ike (RA) na ndị okenye azaghachighị nke ọma, ma ọ bụ ndị na-anabataghị otu ma ọ bụ karịa ọrịa na-agbanwe ọgwụ antirheumatic.
Nkọwapụta (n'ime ụlọ)
| Ihe | Nkọwapụta |
| Ọdịdị | Uzuzu crystalline ọcha ma ọ bụ na-acha ọcha |
| njirimara | IR, HPLC |
| Mmiri | ≤1.5% |
| Ihe ndị emetụtara | TOFA 06 ≤0.15% |
| Tofacitinib trans isomer ≤0.15% | |
| Tofacitinib dehydrogenated ≤0.15% | |
| Ọdịghị ọcha ọ bụla amabeghị ≤0.10% | |
| Mkpokọta adịghị ọcha: ≤1.0% | |
| Ihe mgbaze fọdụrụnụ | Ethanol ≤5000ppm |
| Benzene ≤2ppm | |
| Toluene ≤890ppm | |
| Chlroroethane ≤1000ppm | |
| N, N-Dimethylformamide ≤800ppm | |
| Palladium ≤10ppm | |
| Dichloromethane ≤600ppm | |
| Sulfated uyi | ≤0.1% |
| Ọla dị arọ | ≤10ppm |
| Ụlọ ọrụ HPLC | 3S, 4S tofacitinib ≤0.15% |
| Nnwale (na anhydrous ndabere) 98.0-102.0% |
